Some indicators of hemostasis in patients with ischemic heart disease and coronary angioplasty


  • N.V. Storozhuk
  • E.V. Luhovskoy
  • B.H Storozhuk
  • T.M. Platonova
  • I.M. Kolesnikov
Keywords: ischemic heart disease, angioplasty, restenosis, hemostasis, soluble fibrin, D-dimer, protein C, fibrinogen

Abstract

The effect of hemostasis parameters on the development of stent restenosis / thrombosis requires further investigation. The purpose of the paper is to find out the informativeness of activators and inhibitors of the circulating blood system as markers for the development of thrombotic complications in patients with ischemic heart disease and coronary angioplasty. 92 patients (78 men and 14 women) with ischemic heart disease and coronary angioplasty were examined, of which 33 cases suffered from stent restenosis/thrombosis. The patients were simultaneously evaluated for hemostasis parameters (soluble fibrin, D-dimer, protein C, and fibrinogen). It is determined that in patients with ischemic heart disease who have undergone angioplasty in 67.4% of cases there is a significant increase in the level of soluble fibrin with subsequent significant increase in patients with a history of restenosis. It is established that the level of D-dimer in these patients is significantly lower, while in the women it is significantly lower than that of the studied men. The reaction of anticoagulant protein C in 42.4% of patients tends to decrease, taking into consideration that in 80.4% cases there is significant fibrinogenemia. Therefore, the study reveals a significant imbalance in the system of pro- and anticoagulation in this category of patients in favor of the coagulation link, and the hemostatic parameters studied in the complex can be used as informative integral markers of thrombinemia.

References

1. Didyk, O. P. & Rasputina, L. V. (2016). Trombozy stenta: analiz poshyrenosti ta predyktory vynyknennia [Stent thrombosis: An analysis of prevalence and predictors of occurrence]. Ukrainskyi kardiolohichnyi zhurnal (dodatok) – Ukrainian Cardiology Magazine (Annex), 3, 157–7.

2. Luhovskoi, E. V., Komisarenko, S. V., Platonova, T. M., Rublenko, A. M., Fishchenko V. O. … Kolesnikova, I. M. (2013). Vyznachennia vmistu rozchynnoho fibrynu ta D–dymeru dlia prohnozuvannia trombotychnykh uskladnen za endoprotezuvannia kulshovoho suhloba [Determination of the content of soluble fibrin and D-dimer to predict thrombotic complications for the hip joint prosthetics]. Laboratorna diahnostyka – Laboratory diagnostics, 64 (2), 3–8.

3. Mostovoi, Yu. M., Rasputina, L. V., Didyk, O. P., Danylchuk, I. V. & Solomonchuk, A. H. (2015). Shcho obraty: oryhinalnyi klopidohrel abo heneryk? Rozdumy pidtverdzheni praktykoiu [What to choose: the original clopidogrel or generic? Reflections are confirmed by practice]. Kardyolohyia: ot nauky k praktyke – Cardiology: From Science to Practice, 6 (19), 97–108.

4. Pasko, V. S., Kravchenko, A. M., Benielovskaia, L. K. & Kostiukevych, O. M. (2016). Vplyv podviinoi antytrombotsytarnoi terapii na funktsiiu trombotsytiv u khvorykh na ishemichnu khvorobu sertsia z HKh [The Effect of Double Antiplatelet Therapy on the Thrombocyte Function in Patients with Coronary Heart Disease]. Ukrainskyi kardiolohichnyi zhurnal (dodatok) – Ukrainian Cardiology Magazine (Annex), 3, 58–9.

5. Rublenko, A. M., Urvant, L. P., Makohonenko, Ye. M., Platonova, T. M., Tsap, P. Yu., Chernyshenko, T. M. … Luhovskoi, E. V. (2011). Vplyv aktyvatoru proteinu S na zahalnyi hemostatychnyi potentsial plazmy krovi za endoprotezuvannia tazostehnovoho suhloba [Influence of protein C activator on total hemostatic potential of blood plasma for endoprosthetics of hip joint]. Ukrainskyi biokhimichnyi zhurnal – Ukrainian Biochemical Journal, 83 (5), 32–9.

6. Storozhuk, L. O., Shevchuk, S. V., Storozhuk, B. H., Zaichko, N. V., Luhovskoi, E. V. … Platonova, T. M. (2017). Kliniko-laboratorna diahnostyka trombofilii u khvorykh z KhKhN VD stadii, shcho perebuvaiut na prohramnomu hemodializi (metodychni rekomendatsii) [Clinical and laboratory diagnostics of thrombophilia in patients with CKD of VD stage, which are on program hemodialysis (methodical recommendations)]. Vinnytsia: FOP Rohalska I.O.

7. Tishko, V. V., Tyrenko, V. V., Kozlov, K. L., Sokolov, A. A., Zheleznyak, I. S., Kravchuk, V. N. ... Lyubimov, A. I. (2014). Multidisciplinarnyj podhod k vedeniyu pocientov vysokogo riska posle povtornyh revaskulyarizacij miokarda [Multidisciplinary approach to the management of high-risk patients after repeated myocardial revascularization]. Klinicheskaya gerontologiya – Clinical gerontology, 20 (9–10), 40–4. Vzyato s http://publish.newdiamed.ru/arhive/kg09_1014_web.pdf.

8. Fedorchenko, A. N., Osiev, A. G., Promononov, A. V., Stolyarov, D. P. & Kochkina, K. V. (2018). Chastota razvitiya restenoza posle angioplastiki okklyuziruyushij i neokklyuziruyushij porazhenij koronarnyh arterij [The incidence of restenosis after angioplasty is occlusive and non-occlusive lesions of the coronary arteries]. Kubanskij nauchnyj medicinskij vesnik – Kuban Scientific Medical Journal, 6 (105), 105–9.

9. Furkalo, S. N. (2012). Koronarnoe stentirovanie u bolnyh stabilnymi formami IBS. Danye dokazatelnoj mediciny i sobstvennye rezultaty [Coronary stenting in patients with stable forms of coronary artery disease. Evidence-based medicine and its own results]. Kardiologiya: ot nauki k praktike – Cardiology: from science to practice, 2, 96–106.

10. Pyrogova, L. V., Chernyshenko, T. M., Kolesnikova, I. M., Platonova, T. M., Bereznitsky, G. K., Makogonenko, Y. M. (2016). Level of overall haemostasis potential in donor and patient in pathology. The Ukrainian Biochemical Journal, 88 (2), 56–75. Retrieved from http://nbuv.gov.ua/UJRN/BioChem_2016_88_2_8
Published
2018-09-28
How to Cite
Storozhuk, N., Luhovskoy, E., Storozhuk, B., Platonova, T., & Kolesnikov, I. (2018). Some indicators of hemostasis in patients with ischemic heart disease and coronary angioplasty. Reports of Vinnytsia National Medical University, 22(3), 446-449. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2018-22(3)-09